A trading update for FY 2021 indicates unaudited revenues of £1.5m and year-end cash of £12.1m. Whilst revenues were markedly below our £9.2m forecast, set in Q1 2021, they are not wholly unexpected and in line with market commentators’ changes in Q4 2021. A 60% increase in Feraccru packs sold in Europe and further encouraging news of contracted commercial lives under coverage in the US rising to 60m from 40m in mid-December, suggests strong momentum going into 2022. The increased awareness (now ....
17 Feb 2022
Shield Therapeutics - FY 2021 trading update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - FY 2021 trading update
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-3.7%) | Mkt Cap: 11.5m
- Published:
17 Feb 2022 -
Author:
Mark Brewer -
Pages:
13
A trading update for FY 2021 indicates unaudited revenues of £1.5m and year-end cash of £12.1m. Whilst revenues were markedly below our £9.2m forecast, set in Q1 2021, they are not wholly unexpected and in line with market commentators’ changes in Q4 2021. A 60% increase in Feraccru packs sold in Europe and further encouraging news of contracted commercial lives under coverage in the US rising to 60m from 40m in mid-December, suggests strong momentum going into 2022. The increased awareness (now ....